MOLECULAR DIAGNOSIS OF CANCER MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-148962 | Others
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Molecular diagnosis of cancer Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL MOLECULAR DIAGNOSIS OF CANCER MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL MOLECULAR DIAGNOSIS OF CANCER MARKET
7.1 GLOBAL MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA MOLECULAR DIAGNOSIS OF CANCER MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Invitae
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 AstraZeneca
16.3 Bio-Techne
16.4 Foundation Medicine
16.5 Guardant Health
16.6 GenomOncology
16.7 10X Genomics
16.8 Danaher
16.9 CytoTrack
16.10 Siemens
16.11 Biodesix
16.12 Biocartis
16.13 Luminex
16.14 Roche
16.15 MDxHealth
16.16 Thermo Fisher Scientific
16.17 Abbott Laboratories
16.18 ICON Plc
16.19 PlexBio
16.20 Merck
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Major Types Coveredother
Pharmacogenomic diagnosis
Liquid biopsy
Major Downstream Industry Covered
Cancer of urinary system
Cancer of sports system
Cancer of digestive system
other
Cancer of reproductive system
Cancer of respiratory system
Cancer of blood circulation system
Companies
Invitae
AstraZeneca
Bio-Techne
Foundation Medicine
Guardant Health
GenomOncology
10X Genomics
Danaher
CytoTrack
Siemens
Biodesix
Biocartis
Luminex
Roche
MDxHealth
Thermo Fisher Scientific
Abbott Laboratories
ICON Plc
PlexBio
Merck
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.